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Abstract
Background: Histone deacetylases (HDACs) have been associated with malignant tumor development and progression
in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The
present study aimed to evaluate the clinical significance of HDAC-1, −2, −4 and −6 protein expression in
pancreatic adenocarcinoma.
Methods: HDAC-1, −2, −4 and −6 protein expression was assessed immunohistochemically on 70 pancreatic
adenocarcinoma tissue specimens and was statistically analyzed with clinicopathological characteristics and
patients’ survival.
Results: Enhanced HDAC-1 expression was significantly associated with increased tumor proliferative capacity
(p = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632). Elevated HDAC-4
expression was significantly associated with the absence of organ metastases (p = 0.0453) and borderline with
the absence of lymph node metastases (p = 0.0571) and tumor proliferative capacity (p = 0.0576). Enhanced
HDAC-6 expression was significantly associated with earlier histopathological stage (p = 0.0115) and borderline
with smaller tumor size (p = 0.0864). Pancreatic adenocarcinoma patients with enhanced HDAC-1 and −6
expression showed significantly longer survival times compared to those with low expression (p = 0.0022 and
p = 0.0113, respectively), while a borderline association concerning HDAC-2 expression was noted (p = 0.0634).
Conclusions: The present study suggested that HDACs may be implicated in pancreatic malignant disease
progression, being considered of clinical utility with potential use as therapeutic targets.
Keywords: Histone deacetylase, Pancreatic adenocarcinoma, Immunohistochemistry, Clinicopathological
parameters, Patients’ survival
Background
Acetylation of DNA-bound core histones constitutes an es-
sential mechanism of epigenetic transcriptional regulation
[1, 2]. Histone acetylation is regulated by two opposing
classes of enzymes: histone acetyltransferases (HATs),
which transfer the acetyl moiety from acetyl coenzyme A
to specific lysine residues of histones and histone deacety-
lases (HDACs), which catalyze their removal in order to
re-establish the positive charge in the histones [2, 3]. To
date, a total of 19 HDACs have been identified in humans,
being grouped into three distinct classes, with correspond-
ing homology to the yeast S. Cerevisiae. Among them, class
I HDACs is represented by HDAC-1, −2, −3, and −8, with
homology to the yeast Rpd3, where the catalytic domain
constitutes the majority of the protein, and class II HDACs
comprises of HDAC-4, −5, −6, −7, −9, and 10 [1–3].
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Both HATs and HDACs have been considered as
crucial regulators of cell proliferation, differentiation
and apoptosis in various hematological and solid ma-
lignancies [4, 5]. Aberrant deacetylation of histones
by enhanced HDAC activity in human tumors has
been shown to lead to conformational changes within
nucleosome, which results in transcriptional repres-
sion of genes involved in differentiation and negative
regulation of cell proliferation, migration and metasta-
sis [6, 7]. Importantly, several HDAC inhibitors
(HDACIs) have been shown to induce cell cycle
growth arrest in both normal and transformed cells
and activate the extrinsic and intrinsic pathways of apop-
tosis [6, 7]. Both in vitro and in vivo data and ongoing
clinical trials have recently revealed that HDACIs could be
used against different solid tumors and hematological
malignancies, consisting one of the most promising classes
of new anticancer agents [8–13].
Pancreatic cancer is one of the most lethal malignant
tumors presenting extremely poor prognosis [14, 15].
Tumor resection is performed in 9–36 % of patients and
the 5-year survival rate of patients who have undergone
resection is only 19–24 % [14, 15]. Hence, there is a
strong demand for novel specific markers to be explored
in respect to pancreatic adenocarcinoma patients’ man-
agement and prognosis. Moreover, chemotherapy, such
as treatment with 5-fluorouracil or gemcitabine, is
not potentially capable of contributing to significant
survival benefit according to the available literature
data, although their combination is associated with a
small survival advantage of about 4 to 8 weeks [16].
In this aspect, the establishment of alternative thera-
peutic approaches for the treatment of pancreatic
cancer remains a great challenge.
In the last few years, HDACs have been shown to be
overexpressed in many human malignancies, including
mobile tongue, thyroid, lung, gastric, colorectal, breast,
ovarian, endometrial, pancreatic, prostate, brain and
renal cell carcinomas as also in hematological malignan-
cies [17–31]. Notably, most of the above studies sug-
gested that HDACs expression was directly associated
with tumor dedifferentiation, enhanced proliferation and
invasion, disease stage and patients’ prognosis [17–31].
However, the available data so far, evaluating the immu-
nohistochemical expression of HDACs in pancreatic
adenocarcinoma remain scarce, being only restricted to
HDAC-1 member [24]. In view of the above consider-
ations, the present study aimed to assess immunohisto-
chemically the expression of HDAC-1, −2, −4 and −6 in
tumoral specimens obtained from pancreatic adenocar-
cinoma patients. We also aimed to evaluate the associ-
ation of HDAC-1, −2, −4 and −6 expression with
clinicopathological characteristics, tumor proliferative
capacity and patients’ survival.
Methods
Clinical material
Seventy pancreatic ductal adenocarcinoma specimens
obtained from equal number of patients who underwent
surgical resection due to pancreatic cancer were in-
cluded in this study. The study was approved by the in-
stitutional ethical committee of the Medical School of
the University of Athens. Informed consent to use their
biological samples and clinical data for research pur-
poses was signed by all patients under study. None of
the patients received any kind of anti-cancer treatment
prior to surgery. Forty-four of the patients were men
(62.9 %) and 26 women (37.1 %), with a mean age of
66.77 ± 8.94 years (range 33–84 years). The cases were
classified based on the World Health Organization cri-
teria for histological grading as: well in 9 (12.9 %); mod-
erately in 51 (72.8 %); poorly differentiated in 10
(14.3 %) [32]. Tumor staging was assessed using the 5th
edition of the Tumour, Node, Metastasis (TNM) and the
American Joint Committee on Cancer (AJCC) Grouping
system [33, 34]. In fact, tumors were classified as: T1 in
4 (5.7 %), T2 in 8 (11.4 %), T3 in 48 (68.6 %) and T4 in
10 (14.3 %) cases. Thirty-three (47.1 %) were lymph node
negative (N0), and 37 (52.9 %) were regional lymph node
positive (N1). Organ metastasis was noted in 4 (5.7 %)
out of 70 patients examined. According to the AJCC
classification, 10 (14.3 %) cases were characterized as
stage I, 46 (65.7 %) as stage II, 10 (14.3 %) as stage III
and 4 (5.7 %) as stage IV. The patients were followed up
until death for a time interval of 4 up to 21 months with
a mean survival time of 8.69 ± 3.57 months. Overall sur-
vival was defined as the time interval between the date
of surgery and the date of death due to pancreatic
adenocarcinoma. At the time of the last follow-up, all
patients had died from the disease.
Immunohistochemistry
Immunostainings for HDAC-1, −2, −4 and −6 were per-
formed on individual formalin-fixed, paraffin-embedded
pancreatic adenocarcinoma tissue sections using rabbit
polyclonal anti-HDAC-1 (H-51, sc-7872, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-HDAC-2
(H-54, sc-7899, Santa Cruz Biotechnology) IgG antibodies
and mouse monoclonal anti-HDAC-4 (A-4, sc-46672,
Santa Cruz Biotechnology) IgG2b and anti-HDAC-6 (D-
11, sc-28386, Santa Cruz Biotechnology) IgG2a antibodies.
Briefly, 4 μm thick tissue sections were dewaxed in xylene
and were brought to water through graded alcohols. Anti-
gen retrieval was performed by microwaving slides in
10 mM citrate buffer (pH 6.1) for 15 min (min) at high
power, according to the manufacturer’s instructions. To
remove the endogenous peroxidase activity, sections were
then treated with freshly prepared 0.3 % hydrogen perox-
ide in methanol in the dark, for 30 min, at room
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temperature. Non-specific antibody binding was blocked
using Sniper, a specific blocking reagent for mouse and
rabbit primary antibodies (Sniper, Biocare Medical,
Concord, California, USA) for 5 min. The sections were
incubated for 1 h (h), at room temperature, with the pri-
mary antibodies against HDAC-1, −2, −4 and −6 diluted
1:200 in phosphate buffered saline (PBS) according to the
manufacturer’s instructions. Sections were then incubated
at room temperature with biotinylated linking reagent
(Biocare Medical) for 10 min, followed by incubation with
peroxidase-conjugated streptavidin label (Biocare Medical)
for 10 min. The resultant immune peroxidase activity was
developed using a DAB substrate kit (Vector Laboratories,
California, USA) for 10 min. Sections were counterstained
with Harris’ hematoxylin and mounted in Entellan
(Merck, Darmstadt, Germany). Appropriate negative con-
trols were performed by omitting the primary antibody
and/or substituting it with an irrelevant anti-serum. As
positive control, mobile tongue squamous and
thyroid carcinoma tissue sections with known in-
creased HDAC-1, −2, −4 and −6 expression were
used [17, 18]. Isotype controls were not performed.
The tumour cells’ proliferative capacity was assessed
by Ki-67 immunohistochemical expression, as previ-
ously described [17, 18].
Evaluation of immunohistochemistry
Immunohistochemical evaluation was performed by
counting at least 1000 tumor cells in each case by two
independent observers (S.T. and E.P.) blinded to the
clinical data, with complete observer agreement. Speci-
mens were considered “positive” for HDAC-1, −2, −4
and −6 when more than 5 % of tumor cells within the
section were positively stained. HDAC-1, −2, −4 and −6
immunoreactivity was scored according to the percent-
age of positive tumor cells as 0: negative staining- 0–4 %
of cells positive; 1: 5–24 % of cells positive; 2: 25–49 %
of cells positive; 3: 50–100 % of cells positive, and its in-
tensity as 0: negative staining, 1: mild staining; 2: inter-
mediate staining; 3: intense staining. Finally, the
expression of HDAC-1, −2, −4 and −6 was classified as
low; if the total score was 0 or 2 and high; if the total
score was ≥3 [17, 18]. In this way, we ensure that each
group has a sufficient and more homogeneous number
of cases in order to be comparable with the other groups
[17, 18]. Ki-67 immunoreactivity was classified according
to the percentage of positively stained tumor nuclei
exceeding the mean percentage value into two cat-
egories (below and over median value), as previously
reported [17, 18].
Statistical analysis
Chi-square test was used to assess the associations of
HDAC-1, −2, −4 and −6 proteins’ expression with
clinicopathological variables. Survival curves were con-
structed using the Kaplan-Meier method and the differ-
ences between the curves were compared by the log
rank test. A Cox proportional-hazard regression model
was developed to evaluate the association between the
potential prognostic marker and overall survival, at
multivariate level. A p-value less than 0.05 was consid-
ered the limit of statistical significance. SPSS for
Windows Software was used for all analyses (SPSS Inc.,
2003, Chicago, USA).
Results
Clinical significance of HDAC-1 expression in pancreatic
adenocarcinoma
Forty-five (64.3 %) out of 70 pancreatic adenocarcinoma
cases were found HDAC-1 positive. The pattern of
HDAC-1 distribution was nuclear in all positive cases
(Fig. 1a). High HDAC-1 expression was noted in 28
(40.0 %) out of 70 pancreatic adenocarcinoma cases.
Non-neoplastic sites of pancreatic tissues were found
negative for HDAC-1 (data not shown).
In crosstabulation, high HDAC-1 expression was sig-
nificantly associated with increased tumor proliferative
capacity (Table 1, p = 0.0238). High HDAC-1 expression
was borderline more frequently observed in pancreatic
adenocarcinoma patients with absence of lymph node
metastases (Table 1, p = 0.0632). High HDAC-1 expres-
sion was also more frequently observed in pancreatic
adenocarcinoma patients presenting smaller tumor size
and earlier histopathological stage, at a non significant
level though (Table 1, p = 0.1544 and p = 0.1127,
respectively).
Kaplan-Meier survival curves indicated that pancreatic
adenocarcinoma patients presenting high HDAC-1
expression had significantly longer survival times
compared to those with low expression (Fig. 2a,
Table 2, log-rank test, p = 0.0022). In multivariate ana-
lysis, histopathological stage but not HDAC-1 expres-
sion was identified as independent prognostic factor
of patients’ survival (Table 3, Cox-regression analysis,
p < 0.001and p = 0.0521, respectively).
Clinical significance of HDAC-2 expression in pancreatic
adenocarcinoma
Forty-nine (74.2 %) out of 70 pancreatic adenocarcinoma
cases were found HDAC-2 positive. The pattern of
HDAC-2 distribution was nuclear in all positive cases
(Fig. 1b). High HDAC-2 expression was noted in 35
(50.0 %) out of 70 pancreatic adenocarcinoma cases.
Non-neoplastic sites of pancreatic tissues were found
negative for HDAC-2 (data not shown).
In crosstabulation, HDAC-2 expression was not sig-
nificantly associated with any clinicopathological param-
eters examined (Table 1). High HDAC-2 expression was
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more frequently observed in pancreatic adenocarcin-
oma patients presenting smaller tumor size, absence
of lymph node metastases and earlier histopatho-
logical stage, at a non significant level though (Table 1,
p = 0.2046, p = 0.2312 and p = 0.2320, respectively).
Kaplan-Meier survival curves indicated that pancreatic
adenocarcinoma patients presenting high HDAC-2
expression had marginally longer survival times com-
pared to those with low expression (Fig. 2b, Table 2,
log-rank test, p = 0.0634).
Concomitant HDAC-1/HDAC-2 expression was not
significantly associated with any clinicopathological
parameters (p > 0.05, data not shown). Kaplan-Meier
survival curves indicated that pancreatic adenocarcin-
oma patients presenting concomitant high HDAC-1/
HDAC-2 expression had significantly longer survival
times compared to those with low expression (log-rank
test, p = 0.0255). Concomitant HDAC-1/HDAC-2 ex-
pression was not remained significant in multivariate
analysis (p > 0.05, data not shown).
Clinical significance of HDAC-4 expression in pancreatic
adenocarcinoma
Forty-seven (69.1 %) out of 70 pancreatic adenocarcin-
oma cases were found HDAC-2 positive. The pattern of
HDAC-4 distribution was cytoplasmic in all positive
cases (Fig. 1c). High HDAC-4 expression was noted in
34 (48.6 %) out of 70 pancreatic adenocarcinoma cases.
Non-neoplastic sites of pancreatic tissues were found
negative for HDAC-4 (data not shown).
In crosstabulation, high HDAC-4 expression was
significantly associated with the absence of organ
metastases (Table 4, p = 0.0453). High HDAC-4 ex-
pression was more frequently observed in pancreatic
adenocarcinoma patients with absence of lymph node
metastases and increased tumor proliferative capacity,
at a non significant level though (Table 4, p = 0.0571
and p = 0.0576, respectively). High HDAC-4 expres-
sion was also more frequently observed in pancreatic
adenocarcinoma patients presenting earlier histo-
pathological stage, at a non significant level though
(Table 4, p = 0.2818). HDAC-4 expression was not
associated with patients’ survival (Fig. 2c, Table 2,
log-rank test, p = 0.5061).
Clinical significance of HDAC-6 expression in pancreatic
adenocarcinoma
Forty-one (63.1 %) out of 70 pancreatic adenocarcinoma
cases were found HDAC-6 positive. The pattern of
HDAC-6 distribution was cytoplasmic in all positive
cases (Fig. 1d). High HDAC-6 expression was noted in
31 (44.3 %) out of 70 pancreatic adenocarcinoma cases.
Non-neoplastic sites of pancreatic tissues were found
negative for HDAC-6 (data not shown).
In crosstabulation, HDAC-6 expression was signifi-
cantly associated with earlier histopathological stage
(Table 2, p = 0.0115). High HDAC-6 expression was
more frequently observed in pancreatic adenocarcin-
oma patients with smaller tumor size and absence of
organ metastases, at a non significant level though
(Table 4, p = 0.0864 and p = 0.0663, respectively). High
HDAC-6 expression was more frequently observed in
younger and female pancreatic adenocarcinoma pa-
tients, as well as in those with absence of lymph node
Fig. 1 Representative immunostainings of pancreatic adenocarcinoma tumor cells presenting high expression of a. HDAC-1, b. HDAC-2,
c. HDAC-4 and d. HDAC-6. Streptavidin-biotin-peroxidase, DAB chromogen, Harris hematoxylin counterstain (original magnification X200)
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metastases, at a non significant level though (Table 4,
p = 0.2920, p = 0.2157 and p = 0.1026, respectively).
Kaplan-Meier survival curves indicated that pancreatic
adenocarcinoma patients presenting high HDAC-6
expression had significantly longer survival times
compared to those with low expression (Fig. 2d, Table 2,
log-rank test, p = 0.0113). In multivariate analysis, histo-
pathological stage but not HDAC-6 expression was iden-
tified as independent prognostic factor of patients’
survival (Table 5, Cox-regression analysis, p < 0.001and
p = 0.2193, respectively).
Concomitant HDAC-1/HDAC-2/HDAC-4/HDAC-6
expression was not associated with either any clinico-
pathological parameter or patients’ prognosis (p > 0.05,
data not shown).
Discussion
In the last few years, HDACs have been considered
as crucial regulators of cell proliferation, differenti-
ation and apoptosis in various hematological and solid
malignancies [6–13]. HDACs overexpression has been
described in several types of human malignancy, be-
ing associated with crucial clinicopathological parame-
ters for patients’ management and prognosis [17–31].
However, the assessment of their clinical significance
in pancreatic adenocarcinoma remains scarce.
In view of above considerations, the present study
assessed for the first time the clinical significance of
HDAC-1, −2, −4 and −6 expression in pancreatic adeno-
carcinoma. We found that approximately half of the
examined cases presented high HDAC-1, −2, −4 and −6
expression (40.0 %, 50.0 %, 48.6 % and 44.3 %, respect-
ively). Moreover, all the examined cases showed negative
HDAC-1, −2, −4 and −6 immunostaining in non-
neoplastic sites of pancreatic tissues. The elevated
expression levels of HDAC-1, −2, −4 and −6 in pancreatic
adenocarcinoma may reinforce the therapeutic utility of
HDAC targeting in pancreatic cancer chemoprevention,
taking into consideration the anti-cancer properties of
HDACIs in cell proliferation, differentiation and apoptosis
Table 1 Associations of HDAC-1 and −2 expression with clinicopathological parameters in 70 pancreatic adenocarcinoma patients
Clinicopathological
characteristics
HDAC-1 expression HDAC-2 expression
Low (%) High (%) p-value Low (%) High (%) p-value
N = 70 42 (60.0) 28 (40.0) 35 (50.0) 35 (50.0)
Age (mean ± SD;ys) 0.4880 0.8082
≤66.77 ± 8.94 yrs 16 (22.9) 13 (18.6) 14 (20.0) 15 (21.4)
>66.77 ± 8.94 yrs 26 (37.1) 15 (21.4) 21 (30.0) 20 (28.6)
Gender 0.4191 0.6207
Male 28 (40.0) 16 (22.9) 23 (32.9) 21 (30.0)
Female 14 (20.0) 12 (17.1) 12 (17.1) 14 (20.0)
Histopathological grade 1.0000 0.4945
I + II 36 (51.4) 24 (34.3) 29 (41.4) 31 (44.3)
I II 6 (8.6) 4 (5.7) 6 (8.6) 4 (5.7)
pT 0.1544 0.2046
T1 + T2 5 (7.1) 7 (10.0) 4 (5.7) 8 (11.4)
T3 + T4 37 (52.9) 21 (30.0) 31 (44.3) 27 (38.6)
pN 0.0632 0.2312
0 16 (22.9) 17 (24.3) 19 (27.1) 14 (20.0)
1 26 (37.1) 11 (15.7) 16 (22.9) 21 (30.0)
pM 0.5282 1.0000
0 39 (55.7) 27 (38.6) 33 (47.1) 33 (47.1)
1 3 (4.3) 1 (1.4) 2 (2.9) 2 (2.9)
pStage 0.1127 0.2320
I + II 31 (44.3) 25 (35.7) 26 (37.1) 30 (42.9)
III + IV 11 (15.7) 3 (4.3) 9 (12.9) 5 (7.1)
Ki-protein statement 0.0238 0.4703
≤ median value 28 (40.0) 11 (15.7) 21 (30.0) 18 (15.7)
> median value 14 (20.0) 17 (24.3) 14 (20.0) 17 (24.3)
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[6–13]. In this context, the cdk inhibitor p21 was shown
to be of the most commonly induced genes in various
pancreatic cancer cell lines by several HDACIs [6, 8].
Transcriptional induction of p21 was associated with G1
cell cycle arrest and growth inhibition. HDACIs also re-
sulted in cell cycle arrest and growth inhibition by tran-
scriptional activation of other cell cycle regulatory genes
such as p16, p27, cyclin E and gelsolin, while inhibition of
cyclins A, B1, D1 and D2 were also noted in many cancer
cell lines. Another mechanism of action for HDACIs con-
cerns the up-regulation of pro-apoptotic proteins Bax,
Bad and Bim, and the down-regulation of the anti-
apoptotic ones such as Bcl-2, Bcl-XL and surviving [6–8].
HDACIs also reduced the expression of angiogenetic fac-
tors, such as VEGF receptors −1 and −2, and affected the
expression of a panel of metastasis promoting genes [6, 8].
Additionally, HDACIs exhibited antiproliferative effects in
cancer animal models. Various pancreatic carcinoma cell
lines were grown as xenografts in nude mice and treated
with HDACIs [6–8]. For most cell lines used, anti-tumor
activity and dose-dependent response were observed, with
reduction of cell proliferation and induction of apoptosis.
Notably, the reduction of pancreatic tumor weight was
achieved with minimal toxicity [6–8].
In the present study, HDAC-1 and −2 subcellular dis-
tribution was nuclear, whereas HDAC-4 and −6 distribu-
tion was cytoplasmic. In accordance to the above
findings, class I HDACs are mostly localized within the
nucleus due to the lack of a nuclear export signal,
whereas class II HDACs shuttle between nucleus and
cytoplasm in response to certain cellular signals [2, 3].
In this aspect, knockout analysis of different class I and
class II HDAC proteins indicated that class I HDACs
play a role in cell survival and proliferation, whereas
class II HDACs may have tissue-specific roles [2, 3].
The present study further showed that HDAC-1, −2, −4
and −6 immunohistochemical expression was associ-
ated with clinicopathological characteristics, which are
Fig. 2 Kaplan-Meier survival analysis stratified according to a. HDAC-1, b. HDAC-2, c. HDAC-4 and d. HDAC-6 expression in pancreatic
adenocarcinoma patients
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considered crucial for patients’ management and
prognosis. Notably, elevated HDAC-1 expression was
significantly associated with increased tumor prolifera-
tive capacity, enhanced HDAC-4 expression with the
absence of distant metastases and elevated HDAC-6
expression with earlier histopathological stage. Trends
of correlation with lymph node metastases and tumor
size were also obtained. Enhanced HDAC-1 and −6 ex-
pression was further associated with better overall pa-
tients’ survival. In agreement with the present findings,
recent studies supported evidence that HDACs expression
was directly associated with tumor differentiation,
proliferation and invasion, disease stage and patients’
prognosis in several human malignancies [6, 8, 35].
According to a comprehensive and critical review by
Weichert, the majority of the existing studies reported an
enhanced expression of class I HDAC isoforms in solid
human tumours, both on mRNA and protein level [35]. In
most studies, class I HDAC expression was increased in
locally advanced, dedifferentiated and strongly proliferat-
ing tumours [35]. In some but not all tumour entities
elevated class I HDAC expression was associated with
poor patient survival [35]. However, an association of
elevated class I HDAC expression with improved patients’
prognosis for selected tumour types has also been re-
ported [35]. In contrast to class I isoforms, expression of
class II HDACs has been found reduced in tumours and
high expression of these isoforms in some tumour types
predicted better patients’ outcome [35]. In fact and in
accordance with the present study, elevated HDAC-1
expression was associated with absence of axillary lymph
node involvement, smaller tumor size, well tumor differ-
entiation and better disease-free and overall survival in
breast cancer [28]. Moreover, another study documented
that enhanced HDAC-6 expression was associated with
smaller tumor size and better patients’ survival in invasive
breast cancer [36].
Concerning pancreatic adenocarcinoma, only one
study conducted on 55 cases has currently evaluated the
clinical significance of HDAC-1 member [24]. In this
study, enhanced HDAC-1 expression was significantly
associated with tumor high histological grade and in-
creased proliferative capacity, as also with advanced
TNM stage and shorter patients’ survival [24]. Although
inverse correlations were reported by Wang et al. [25]
and us, both studies support evidence for the clinical
utility of HDAC-1 expression in pancreatic adenocarcin-
oma. The discrepancies in the results between the stud-
ies could be ascribed to the lower number of pancreatic
adenocarcinoma cases (N = 55) used in the above
study compared to our present work (N = 70), as also
to the different primary antibody used to detect
HDAC-1 immunoreactivity and the different demo-
graphics. Moreover, in the above study the evaluation
criteria to semi-quantify HDAC-1 expression was
based on the percentage of positively stained tumor
cells, whereas in our work they were based on both
the percentage of positively stained tumor cells and
the staining intensity.
Recently, HDACIs have been introduced into clinical
trials, especially in pre-treated and multiply relapsed
patients at an advanced cancer stage [5–11]. The first
HDACIs tested in clinical trials have shown encouraging
anti-tumor effects, at dosages well-tolerated by patients.
Importantly, vorinostat was the first HDACI to be
approved for clinical use in treating patients with
Table 3 Multivariate analysis for histopathological stage and
HDAC-1 expression
Clinicopathological variables Overall survival
HR (95 % CI) p-value
Histopathological stage (I + II / III + IV) 0.290 (0.151–0.559) <0.0001
HDAC-1 expression (Low/ ≥ High) 1.672 (0.995–2.809) 0.0521
Table 2 Association of clinicopathological parameters and
HDAC-1, −2, −4 and −6 expression with patients’ survival:
Univariate analysis
Clinicopathological variables Median overall
survival (95 % CI)
p-value
Age <66.77 yrs 8.0 (6.7–9.3) 0.3876
≥66.77 yrs 8.0 (7.2–8.8)
Gender Male 8.0 (7.3–8.7) 0.1343
Female 7.0 (6.2–7.8)
Histopathological grade I + II 8.0 (7.2–8.8) 0.8963
III 7.0 (5.8–8.2)
pT T1 + T2 11.0 (5.3–16.7) <0.0001
T3 + T4 7.0 (6.2–7.8)
pN N0 11.0 (9.8–12.2) <0.0001
N1 7.0 (6.5–7.5)
pM M0 8.0 (7.2–8.8) <0.0001
M1 4.0 (3.9–5.1)
pStage I + II 8.0 (6.9–9.2) <0.0001
III + IV 5.0 (3.9–6.0)
Ki-67 protein statement ≤ median 8.0 (7.1–8.7) 0.8581
> median 7.0 (5.9–8.1)
HDAC-1 expression Low 7.0 (6.3–7.7) 0.0022
High 10.0 (8.8–11.2)
HDAC-2 expression Low 7.0 (5.9–8.1) 0.0634
High 8.0 (6.1–9.9)
HDAC-4 expression Low 8.0 (7.1–8.9) 0.5061
High 8.0 (6.7–9.3)
HDAC-6 expression Low 7.0 (6.2–7.8) 0.0113
High 10.0 (7.6–12.4)
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hematological malignancy (cutaneous T-cell lymphoma)
[37]. HDACIs alone and in combination with a variety of
cytotoxic or other targeted anticancer agents are cur-
rently being tested. Currently, at least ten different
HDACIs are under phase II or III clinical studies for the
treatment of hematological and solid tumors [5–11].
However, clinical data for HDACIs on patients with pan-
creatic cancer remains inadequate and only a few studies
have included patients suffering from this type of
neoplasm [6, 8]. Additionally, the number of pancreatic
cancer patients that entered HDACIs phase II/III trials,
among others with advanced solid tumors, is very
limited. Although HDACIs are recognized as one of the
most promising agents, more studies recruiting for
candidates suffering from pancreatic cancer remain to
determine the efficiency of these therapies [6, 8].
Conclusion
The present study for the first time showed that
elevated HDACs expression were associated with
favourable clinicopathological parameters, such as
earlier histopathological stage, smaller tumor size and
absence of lymph node and organ metastases, which
are considered crucial for pancreatic carcinoma
patients’ management and prognosis. Of even more
clinical significance are the data, supporting the asso-
ciation of HDAC-1 and −6 expression with patients’
survival. These findings provided evidence for a po-
tential important role of HDACs in the biological
mechanisms governing pancreatic malignant disease
progression. The potential implication of HDACs in
the pancreatic adenocarcinoma, along with a few
Table 5 Multivariate analysis for histopathological stage and
HDAC-6 expression
Clinicopathological variables Overall survival
HR (95 % CI) p-value
Histopathological stage (I + II / III + IV) 0.282 (0.143–0.556) <0.0001
HDAC-6 expression (Low/ ≥ High) 0.716 (0.421–1.220) 0.2193
Table 4 Associations of HDAC-4 and −6 expression with clinicopathological parameters in 70 pancreatic adenocarcinoma patients
Clinicopathological
characteristics
HDAC-4 expression HDAC-6 expression
Low (%) High (%) p-value Low (%) High (%) p-value
N = 70 36 (51.4) 34 (48.6) 39 (55.7) 31 (44.3)
Age (mean ± SD;ys) 0.9668 0.2920
≤66.77 ± 8.94 yrs 15 (21.4) 14 (20.0) 14 (20.0) 15 (21.4)
>66.77 ± 8.94 yrs 21 (30.0) 20 (28.6) 25 (35.7) 16 (22.9)
Gender 0.7557 0.2157
Male 22 (31.4) 22 (31.4) 27 (38.6) 17 (24.3)
Female 14 (20.0) 12 (17.1) 12 (17.1) 14 (20.0)
Histopathological grade 0.4347 0.7682
I + II 32 (45.7) 28 (40) 33 (47.1) 27 (38.6)
III 4 (5.7) 6 (8.6) 6 (8.6) 4 (5.7)
pT 0.4573 0.0864
T1 + T2 5 (7.1) 7 (10.0) 4 (5.7) 8 (11.4)
T3 + T4 31 (44.3) 27 (38.6) 35 (50.0) 23 (32.9)
pN 0.0571 0.1026
0 13 (18.6) 20 (28.6) 15 (21.4) 18 (25.7)
1 23 (32.9) 14 (20.0) 24 (34.3) 13 (18.6)
pM 0.0453 0.0663
0 32 (45.7) 34 (48.6) 35 (50.0) 31 (44.3)
1 4 (5.7) 0 (0.0) 4 (5.7) 0 (0.0)
pStage 0.2818 0.0115
I + II 27 (38.6) 29 (41.4) 27 (38.6) 29 (41.4)
III + IV 9 (12.9) 5 (7.1) 12 (17.1) 2 (2.9)
Ki-protein statement 0.0576 0.5379
≤ median value 24 (34.3) 15 (21.4) 23 (32.9) 16 (22.9)
> median value 12 (17.1) 19 (27.1) 16 (22.9) 15 (21.4)
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observations in this field, point out the necessity for
further studies in order to clarify the potential role of
these molecules and their possible use in the established
therapeutic regimens of this type of malignancy.
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